Functions of cholesterol ester transfer protein and relationship to coronary artery disease risk

Journal of Clinical Lipidology

Volumn 4, Issue 5, 2010, Pages 389-393

  Tall, Alan R ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Atherosclerosis; CETP; Clinical trial; Coronary artery disease; HDL

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER A1; ABC TRANSPORTER G1; ALDOSTERONE; APOLIPOPROTEIN B; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; POTASSIUM; TORCETRAPIB;

ANTIINFLAMMATORY ACTIVITY; ARTERY WALL; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FOAM CELL; HUMAN; MACROPHAGE; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CHOLESTEROL ESTER TRANSFER PROTEINS; CORONARY ARTERY DISEASE; DISEASE MODELS, ANIMAL; FOAM CELLS; HUMANS; MICE; POLYMORPHISM, SINGLE NUCLEOTIDE; QUINOLINES; RABBITS; RISK FACTORS;

EID: 77957872214     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2010.08.006     Document Type: Conference Paper

References (17)

1. A.R. Tall Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins J Intern Med 263 2008 256 273
2. Rayner K, Suarez Y, Davalos A, et al. miR-33 coordinates genes regulating cholesterol homeostasis. Science. [In Press].
3. A. Inazu, M.L. Brown, and C.B. Hesler Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation N Engl J Med 323 1990 1234 1238
4. R. Krishna, M.S. Anderson, and A.J. Bergman Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies Lancet 370 2007 1907 1914
5. P. Linsel-Nitschke, and A.R. Tall HDL as a target in the treatment of atherosclerotic cardiovascular disease Nat Rev Drug Discov 4 2005 193 205
6. D. Bailey, R. Jahagirdar, and A. Gordon RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo J Am Coll Cardiol 55 2010 2580 2589
7. M.N. Bradley, C. Hong, and M. Chen Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE J Clin Invest 117 2007 2337 2346
8. S. Lamon-Fava, M.R. Diffenderfer, and P.H. Barrett Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins Arterioscler Thromb Vasc Biol 28 2008 1672 1678
9. P.J. Barter, H.B. Brewer Jr., M.J. Chapman, C.H. Hennekens, D.J. Rader, and A.R. Tall Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis Arterioscler Thromb Vasc Biol 23 2003 160 167
10. L.A. Morehouse, E.D. Sugarman, and P.A. Bourassa Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits J Lipid Res 48 2007 1263 1272
11. A. Thompson, E. Di Angelantonio, and N. Sarwar Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk JAMA 299 2008 2777 2788
12. S. Kathiresan, O. Melander, and D. Anevski Polymorphisms associated with cholesterol and risk of cardiovascular events N Engl J Med 358 2008 1240 1249
13. T.M. Teslovich, K. Musunuru, and A.V. Smith Biological, clinical and population relevance of 95 loci for blood lipids Nature 466 2010 707 713
14. F. Matsuura, N. Wang, W. Chen, X.C. Jiang, and A.R. Tall HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway J Clin Invest 116 2006 1435 1442
15. S.J. Nicholls, E.M. Tuzcu, D.M. Brennan, J.C. Tardif, and S.E. Nissen Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation) Circulation 118 2008 2506 2514
16. L. Yvan-Charvet, J. Kling, and T. Pagler Cholesterol efflux potential and anti-inflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib Arterioscler Thromb Vasc Biol 30 2010 1430
17. P.J. Barter, M. Caulfield, and M. Eriksson Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122